BVS

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Pain Treatments surged 11.5% as management explores strategic alternatives.

Bioventus stock has delivered strong share price gains over the past few years, yet current valuation checks still suggest it screens as relatively cheap on several metrics.

In early August 2026, Bioventus Inc. reported second-quarter sales of US$153.21 million and net income of US$33.44 million, sharply higher than a year earlier, and reaffirmed its full-year 2026 net sales guidance of US$600 million to US$610 million.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks.

Bioventus Inc (BVS) delivers solid Q2 with 4% revenue growth, reduces leverage below 2x, and announces strategic review following unsolicited acquisition interest.

Bioventus (BVS) delivered earnings and revenue surprises of 0.00% and -1.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

The consensus price target hints at a 28.9% upside potential for Bioventus (BVS).

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).